Following on from information provided to NICE by the company in November 2005 the appraisal of Venous thromboembolism (recurrent) - idraparinux sodium [ID395] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 395
Referral date 01 November 2005
Topic area
  • Cardiovascular
  • Therapeutic procedures

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
Final scope published: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC
3rd appraisal committee meeting: TBC
4th appraisal committee meeting: TBC
5th appraisal committee meeting: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
19 January 2023 Discontinued. Following on from information provided to NICE by the company in November 2005 the appraisal of Venous thromboembolism (recurrent) - idraparinux sodium [ID395] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
25 August 2006 This topic was referred by the Department of Health and the Welsh Assembly Government as part of the Institute's 12th wave work programme.
23 July 2007

Idraparinux sodium for the treatment of venous thromboembolism

The manufacturer of idraparinux sodium has advised us that the regulatory strategy in relation to this product is not finalised. The Institute has therefore decided to remove this appraisal from its work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

19 July 2007


For further information on our processes and methods, please see our CHTE processes and methods manual